Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome

Stock Information for Soleno Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soleno Therapeutics Inc.

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Soleno Therapeutics to Present at Upcoming February Investor Conferences
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.